Roivant Sciences Ltd.
General ticker "ROIV" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $17.6B (TTM average)
Roivant Sciences Ltd. follows the US Stock Market performance with the rate: 54.0%.
Estimated limits based on current volatility of 1.5%: low 33.13$, high 34.13$
Factors to consider:
- Total employees count: 721 (-3.9%) as of 2026
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Product development failure, Regulatory and compliance, Manufacturing issues, Capital raising, Acquisition/divestiture risks
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2026-03-31 to 2028-03-30
- 2026-03-31 to 2027-03-31 estimated range: [18.62$, 33.21$]
- 2027-03-31 to 2028-03-30 estimated range: [15.49$, 28.59$]
Financial Metrics affecting the ROIV estimates:
- Positive: with PPE of -28.0 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: 1.34 < Inventory ratio change, % of 3.86
- Negative: negative Industry operating income (median)
- Negative: 69.38 < Shareholder equity ratio, % of 79.31 <= 81.92
- Negative: Investing cash flow per share per price, % of -3.61 <= -2.60
Short-term ROIV quotes
Long-term ROIV plot with estimates
Financial data
| YTD | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|
| Operating Revenue | $32.71MM | $29.05MM | $8.26MM |
| Operating Expenses | $-4,464.32MM | $1,032.35MM | $523.33MM |
| Operating Income | $4,497.03MM | $-1,003.29MM | $-515.07MM |
| Non-Operating Income | $70.82MM | $321.70MM | $250.49MM |
| Interest Expense | $34.78MM | $0.00MM | $0.00MM |
| R&D Expense | $439.91MM | $550.41MM | $681.81MM |
| Income(Loss) | $4,567.86MM | $-681.59MM | $-264.58MM |
| Taxes | $21.50MM | $48.17MM | $133.33MM |
| Other Income(Loss) | $-315.15MM | $373.03MM | $0.00MM |
| Net Income(Loss)* | $4,348.93MM | $-171.98MM | $-299.77MM |
| Stockholders Equity | $5,968.58MM | $4,687.60MM | $4,527.37MM |
| Inventory | $35.25MM | $0.00MM | $0.00MM |
| Assets | $7,222.48MM | $5,436.94MM | $5,708.69MM |
| Operating Cash Flow | $-765.27MM | $-839.45MM | $-750.35MM |
| Capital expenditure | $1.38MM | $4.60MM | $8.21MM |
| Investing Cash Flow | $5,203.62MM | $-1,766.29MM | $-682.33MM |
| Financing Cash Flow | $419.36MM | $-1,219.79MM | $134.24MM |
| Earnings Per Share** | $5.55 | $-0.24 | $-0.43 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.